Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase‐4 inhibitors: Real world evidence from the Nordic EMPRISE study

Aims To evaluate effectiveness and healthcare resource utilization (HCRU) of empagliflozin versus dipeptidyl peptidase‐4 inhibitors (DPP‐4i) in Swedish clinical practice, as part of the EMPRISE EU study (EUPAS27606, NCT03817463). Materials and Methods A non‐interventional, cohort study using retrosp...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, obesity & metabolism obesity & metabolism, 2023-01, Vol.25 (1), p.261-271
Main Authors: Nyström, Thomas, Toresson Grip, Emilie, Gunnarsson, Joel, Casajust, Paula, Karlsdotter, Kristina, Skogsberg, Josefin, Ustyugova, Anastasia
Format: Article
Language:English
Subjects:
Cardiovascular diseases
Cerebral infarction
Cohort Studies
Congestive heart failure
Delivery of Health Care
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - epidemiology
Dipeptidyl-Peptidase IV Inhibitors - therapeutic use
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
Disease prevention
Epidermal growth factor receptors
Glomerular filtration rate
Health care
Humans
Inhibitor drugs
Medicin och hälsovetenskap
Mortality
Myocardial infarction
Original
Peptidase
Regression analysis
Resource utilization
Retrospective Studies
Stroke
Stroke - epidemiology
Stroke - prevention & control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims To evaluate effectiveness and healthcare resource utilization (HCRU) of empagliflozin versus dipeptidyl peptidase‐4 inhibitors (DPP‐4i) in Swedish clinical practice, as part of the EMPRISE EU study (EUPAS27606, NCT03817463). Materials and Methods A non‐interventional, cohort study using retrospectively collected data from Swedish national registries. Adults with type 2 diabetes newly initiated on empagliflozin or DPP‐4i from May 2014 to December 2018 were matched 1:1 using propensity scores based on >180 covariates. Cardiovascular outcomes included hospitalization for heart failure (HHF), all‐cause mortality (ACM), myocardial infarction (MI), stroke and cardiovascular mortality (CVM), as well as their composite outcomes. Renal outcomes included end‐stage renal disease (ESRD), estimated glomerular filtration rate (eGFR) decline to
ISSN:1462-8902
1463-1326
1463-1326
DOI:10.1111/dom.14870